Purple Biotech Ltd (PPBT): Price and Financial Metrics
PPBT Price/Volume Stats
| Current price | $0.51 | 52-week high | $2.10 |
| Prev. close | $0.49 | 52-week low | $0.30 |
| Day low | $0.45 | Volume | 270,900 |
| Day high | $0.59 | Avg. volume | 111,922 |
| 50-day MA | $0.68 | Dividend yield | N/A |
| 200-day MA | $0.96 | Market Cap | 12.94M |
PPBT Stock Price Chart Interactive Chart >
Purple Biotech Ltd (PPBT) Company Bio
Purple Biotech Ltd operates as a pharmaceutical company. The Company discovers and develops medicines, drugs, and other pharmaceutical products for the treatment of osteoarthritis pain and hypertension. Purple Biotech serves customers globally.
Latest PPBT News From Around the Web
Below are the latest news stories about PURPLE BIOTECH LTD that investors may wish to consider to help them evaluate PPBT as an investment opportunity.
Purple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsDr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistan |
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialThis acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has completed patient enrollment in a Phase 2 study of CM24, a multi-functional im |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
Purple Biotech Reports Third Quarter 2023 Financial ResultsInitial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash Runway Extended to 2H 2025 through Recent Financing REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome |
Purple Biotech Fortifies NT219 Patent ProtectionNew patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted a new patent fo |
PPBT Price Returns
| 1-mo | -17.98% |
| 3-mo | -23.00% |
| 6-mo | -62.50% |
| 1-year | -74.24% |
| 3-year | -88.79% |
| 5-year | N/A |
| YTD | -34.62% |
| 2023 | -43.48% |
| 2022 | -64.52% |
| 2021 | 2.10% |
| 2020 | -51.13% |
| 2019 | N/A |
Loading social stream, please wait...